Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-EN | Version v3-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2020-07-22 | 2019-09-17 |
| Drug Identification Number | 02420783 | 02420783 |
| Brand name | FLULAVAL TETRA | FLULAVAL TETRA |
| Common or Proper name | Quadrivalent Influenza Vaccine (Split Virion, Inactivated) | Quadrivalent Influenza Vaccine (Split Virion, Inactivated) |
| Company Name | ID BIOMEDICAL CORPORATION OF QUEBEC | ID BIOMEDICAL CORPORATION OF QUEBEC |
| Ingredients | HAEMAGGLUTININ-STRAIN B HAEMAGGLUTININ-STRAIN B HAEMAGGLUTININ-STRAIN A HAEMAGGLUTININ-STRAIN A | HAEMAGGLUTININ-STRAIN B HAEMAGGLUTININ-STRAIN B HAEMAGGLUTININ-STRAIN A HAEMAGGLUTININ-STRAIN A |
| Strength(s) | 15MCG 15MCG 15MCG 15MCG | 15MCG 15MCG 15MCG 15MCG |
| Dosage form(s) | SUSPENSION | SUSPENSION |
| Route of administration | INTRAMUSCULAR | INTRAMUSCULAR |
| Packaging size | 1 vial X 10 doses | 1 vial X 10 doses |
| ATC code | J07BB | J07BB |
| ATC description | VIRAL VACCINES | VIRAL VACCINES |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | ||
| Actual start date | 2019-09-12 | 2019-09-12 |
| Estimated end date | Unknown | Unknown |
| Actual end date | 2020-07-21 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | 2019-2020 dose yield less than planned. Supply prioritized for public programs. Supply unavailable for private market. | 2019-2020 dose yield less than planned. Supply prioritized for public programs. Supply unavailable for private market. |
| Health Canada comments |